BR0210630A - Sistema fornecedor de liberação prolongada - Google Patents

Sistema fornecedor de liberação prolongada

Info

Publication number
BR0210630A
BR0210630A BR0210630-2A BR0210630A BR0210630A BR 0210630 A BR0210630 A BR 0210630A BR 0210630 A BR0210630 A BR 0210630A BR 0210630 A BR0210630 A BR 0210630A
Authority
BR
Brazil
Prior art keywords
implant
tablet
extended release
release
mini
Prior art date
Application number
BR0210630-2A
Other languages
English (en)
Inventor
Serge R Martinod
Malcolm Brandon
Original Assignee
Smart Drug Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smart Drug Systems Inc filed Critical Smart Drug Systems Inc
Publication of BR0210630A publication Critical patent/BR0210630A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)

Abstract

"SISTEMA FORNECEDOR DE LIBERAçãO PROLONGADA". Aparelho de liberação prolongada incluindo pelo menos um implante de minicomprimido de liberação prolongada, o ou cada implante de minicomprimido incluindo: uma composição farmaceuticamente ativa compreendendo pelo menos um componente farmaceuticamente ativo, e um veículo para este e o ou cada implante de comprimido sendo do tipo comprimido revestido ou bastonete coberto, cada implante de minicomprimido sendo aproximadamente 0,1 a 0,5 vezes o comprimento e/ou diâmetro de um único comprimido de liberação imediata capaz de providenciar o desejado nível sang³íneo limite, dependendo do ativo farmacêutico desejado, e tendo uma carga comercial de aproximadamente 30% a 70% em peso da carga útil total de um tratamento para liberação imediata equivalente durante um período equivalente realizado durante um período equivalente, o aparelho de liberação prolongada providenciando, em uso liberação de ordem zero do ativo farmacêutico.
BR0210630-2A 2001-06-29 2002-07-01 Sistema fornecedor de liberação prolongada BR0210630A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR6024A AUPR602401A0 (en) 2001-06-29 2001-06-29 Sustained release delivery system
PCT/AU2002/000866 WO2003009833A1 (en) 2001-06-29 2002-07-01 Sustained release delivery system

Publications (1)

Publication Number Publication Date
BR0210630A true BR0210630A (pt) 2004-07-27

Family

ID=3829990

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210630-2A BR0210630A (pt) 2001-06-29 2002-07-01 Sistema fornecedor de liberação prolongada

Country Status (9)

Country Link
US (1) US8197839B2 (pt)
EP (1) EP1411905A4 (pt)
JP (1) JP4913321B2 (pt)
CN (1) CN1536988A (pt)
AU (2) AUPR602401A0 (pt)
BR (1) BR0210630A (pt)
CA (1) CA2452075C (pt)
NZ (1) NZ529858A (pt)
WO (1) WO2003009833A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
WO2003022242A1 (en) * 2001-09-11 2003-03-20 Smart Drug Systems Inc Preparation of sustained release pharmaceutical composition
EP1696822B1 (en) * 2003-11-13 2010-03-17 PSivida US Inc. Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
CN101001640A (zh) * 2004-05-31 2007-07-18 斯玛特药物***公司 缓释组合物
CA2575988C (en) 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US20110034498A1 (en) * 2006-03-24 2011-02-10 Mcgovern Karen J Dosing regimens for the treatment of cancer
US20090005869A1 (en) * 2006-12-15 2009-01-01 University Of Virginia Patent Foundation Device which Attaches into a Joint and Carries a Payload of Controlled Release Drugs and Related Method thereof
NZ552290A (en) * 2006-12-21 2009-05-31 Bomac Research Ltd Tablet fomulation
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US20090181997A1 (en) * 2007-12-27 2009-07-16 Grayzel David Therapeutic cancer treatments
CN104059124A (zh) 2007-12-27 2014-09-24 无限药品股份有限公司 立体选择性还原的方法
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US9005649B2 (en) 2009-07-14 2015-04-14 Board Of Regents, The University Of Texas System Methods for making controlled delivery devices having zero order kinetics
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
ITTO20111188A1 (it) 2011-12-22 2013-06-23 Vhit Spa Pompa a cilindrata variabile e metodo di regolazione della sua cilindrata
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
EP3302428A1 (en) 2015-06-04 2018-04-11 Pellepharm Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
FI20155779A (fi) * 2015-10-30 2017-05-01 Solani Therapeutics Ltd Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu
CN111989068A (zh) 2018-05-24 2020-11-24 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
MX2020012458A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
CN110559431B (zh) * 2019-10-11 2023-02-28 南京农业大学 一种巨型艾美耳球虫纳米亚单位疫苗及其制备方法和应用
CN116687882A (zh) * 2023-07-06 2023-09-05 杭州高成生物营养技术有限公司 一种布洛芬缓释小丸及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
DE3681348D1 (de) 1985-06-11 1991-10-17 Teijin Ltd Oral-arzneizubereitung mit retardwirkung.
SE444801B (sv) 1985-06-28 1986-05-12 Johan Magnus Ullman Fender
US4786501A (en) 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US5342622A (en) 1986-05-16 1994-08-30 The State Of Victoria Subdermal biocompatible implants
JPH01500899A (ja) * 1986-05-16 1989-03-30 ザ・ステイト・オブ・ビクトリア 生物適合性インプラント
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
JPH0618958B2 (ja) * 1989-03-08 1994-03-16 株式会社クラレ 多層容器および包装体
ES2042292T3 (es) 1989-03-17 1993-12-01 Pitman-Moore, Inc. Dispositivo de administracion de proteinas macromoleculares por liberacion controlada.
JP2738881B2 (ja) * 1989-06-21 1998-04-08 ブラウン ユニバーシティ リサーチ ファウンデイション 神経治療システム
US5091185A (en) 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
AU660290B2 (en) 1990-08-09 1995-06-22 Endocon, Inc. Multiple drug delivery system
NZ239370A (en) * 1990-08-22 1994-04-27 Merck & Co Inc Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone
IS3778A7 (is) * 1990-10-31 1992-05-02 Amgen Inc. Aðferð til að gefa dýrum vaxtarhormón, þar sem gefnu magni er stýrt
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
JPH06321803A (ja) * 1993-05-17 1994-11-22 Kirin Brewery Co Ltd 水溶性ペプチドホルモンの徐放性製剤
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
FR2745180B1 (fr) 1996-02-23 1998-05-07 Dow Corning Sa Procede de fabrication de dispositifs a liberation controlee
EP1014970A1 (en) * 1997-09-23 2000-07-05 Pfizer Limited Parasiticidal formulations
AUPP279698A0 (en) * 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
EP1098610B1 (en) 1998-07-17 2009-04-15 Pacira Pharmaceuticals, Inc. Biodegradable compositions for the controlled release of encapsulated substances
WO2000013666A1 (en) * 1998-09-05 2000-03-16 Seung Jin Lee Biodegradable particulate polymeric preparation and process for producing thereof
US6756048B1 (en) * 1998-09-10 2004-06-29 Sumitomo Pharmaceuticals Company, Limited Long time drug-sustained release preparation
US6645192B2 (en) * 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
EP2266542A3 (en) 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6596296B1 (en) 1999-08-06 2003-07-22 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
JP4230621B2 (ja) 1999-08-12 2009-02-25 住友ゴム工業株式会社 空気入りタイヤ
TW524696B (en) * 1999-11-10 2003-03-21 Sumitomo Pharma Sustained-release drug formulations
JP4757995B2 (ja) * 1999-11-10 2011-08-24 大日本住友製薬株式会社 薬物放出製剤
WO2001037811A1 (en) * 1999-11-22 2001-05-31 Akzo Nobel N.V. Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
JP4504122B2 (ja) 2004-07-02 2010-07-14 株式会社マキタ 生垣バリカン

Also Published As

Publication number Publication date
WO2003009833A1 (en) 2003-02-06
CN1536988A (zh) 2004-10-13
CA2452075C (en) 2012-08-14
JP2004535473A (ja) 2004-11-25
US20040247643A1 (en) 2004-12-09
AU2002344686B2 (en) 2008-07-31
NZ529858A (en) 2006-02-24
CA2452075A1 (en) 2003-02-06
EP1411905A1 (en) 2004-04-28
AUPR602401A0 (en) 2001-07-26
US8197839B2 (en) 2012-06-12
EP1411905A4 (en) 2008-01-23
JP4913321B2 (ja) 2012-04-11

Similar Documents

Publication Publication Date Title
BR0210630A (pt) Sistema fornecedor de liberação prolongada
ES2155124T3 (es) Composiciones farmaceuticas liquidas a base de hormonas tiroideas.
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
SE9704186D0 (sv) New composition of matter
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
BRPI0611400A8 (pt) Formulações contendo xiloglicano muco-adesivas úteis em dispositivos médicos e em formulações farmacêuticas
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
DE50211045D1 (de) Medizinische aerosolformulierungen
BR0212434A (pt) Dispositivos médicos contendo análogos de rapamicina
DE60220049D1 (de) Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
EE05404B1 (et) Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
HUP9903732A2 (hu) cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására
BR0210631A (pt) Composição farmacêutica de liberação prolongada
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
BR0309115A (pt) Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco
ID18079A (id) Komposisi farmasi yang mengandung bahan pemercepat osteogenesis
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
BR0015225A (pt) Tratamento de enfisema utilizando antagonistas retinóides seletivos para rar
BR0211008A (pt) Combinação de ingrediente ativo, uso de uma combinação de ingrediente ativo e método para a terapia farmacológia de uma substância que causa dependência ou que seja intoxicante
BRPI0414305A (pt) sistema de liberação de drogas por via oral
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
BR0112839A (pt) Composição de eletriptano em partìculas
BR0214159A (pt) Sistema farmacêutico radiopaco de liberação prolongada
DE60320034D1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: VIRBAC CORPORATION (US)

Free format text: TRANSFERIDO DE: SMART DRUG SYSTEMS INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2313 DE 05-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 9/20 (2006.01), A61K 9/2